Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

• Status: Completed
• Trial end date: 2019-06-07
• Target enrollment: 0
• Participant gender: All

Summary

Open label phase 2a study of two week treatment with CDI-31244 and sofosbuvir and veltapasvir followed by four week treatment of sofosbuvir and velpatasvir in individuals with chronic hepatitis C (HCV) genotype 1 (GT1) infection

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cocrystal Pharma, Inc.
• Treatments: Sofosbuvir; Sofosbuvir-velpatasvir drug combination

Criteria

Key Inclusion Criteria:

Documented chronic HCV GT 1 infection; Serum HCV RNA >1,000 IU/mL during screening; Absence of advanced fibrosis or cirrhosis

Key Exclusion Criteria:

Nursing or pregnant women; Active hepatitis B infection; Human immunodeficiency virus (HIV) infection; History of use of any HCV direct-acting antiviral therapy